Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomis... von Reich, Kristian, Teixeira, Henrique D, de Bruin-Weller, Marjolein, Bieber, Thomas, Soong, Weily, Kabashima, Kenji, Werfel, Thomas, Zeng, Jiewei, Huang, Xiaohong, Hu, Xiaofei, Hendrickson, Barbara A, Ladizinski, Barry, Chu, Alvina D, Silverberg, Jonathan I

Volltext

Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis von Kirkham, Bruce W., Kavanaugh, Arthur, Reich, Kristian

Volltext

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey von Lebwohl, Mark G., MD, Bachelez, Hervé, MD, PhD, Barker, Jonathan, MD, FRCP, FRCPath, Girolomoni, Giampiero, MD, Kavanaugh, Arthur, MD, Langley, Richard G., MD, FRCPC, FACP, Paul, Carle F., MD, PhD, Puig, Lluís, MD, PhD, Reich, Kristian, MD, van de Kerkhof, Peter C.M., MD, PhD

Volltext

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study von Guttman-Yassky, Emma, Simpson, Eric L, Reich, Kristian, Kabashima, Kenji, Igawa, Ken, Suzuki, Tetsuya, Mano, Hirotaka, Matsui, Takeshi, Esfandiari, Ehsanollah, Furue, Masutaka

Volltext

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials von Reich, Kristian, Prof, Papp, Kim A, MD, Blauvelt, Andrew, MD, Tyring, Stephen K, Prof, Sinclair, Rodney, Prof, Thaçi, Diamant, Prof, Nograles, Kristine, MD, Mehta, Anish, BA, Cichanowitz, Nicole, MSJ, Li, Qing, PhD, Liu, Kenneth, PhD, La Rosa, Carmen, MD, Green, Stuart, MD, Kimball, Alexa B, Prof

Volltext

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomi... von Reich, Kristian, MD, Armstrong, April W., MD, MPH, Foley, Peter, MD, Song, Michael, MD, Wasfi, Yasmine, MD, PhD, Randazzo, Bruce, MD, PhD, Li, Shu, PhD, Shen, Y.-K., PhD, Gordon, Kenneth B., MD

Volltext

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks von von Stebut, Esther, Reich, Kristian, Thaçi, Diamant, Koenig, Wolfgang, Pinter, Andreas, Körber, Andreas, Rassaf, Tienush, Waisman, Ari, Mani, Venkatesh, Yates, Denise, Frueh, Jennifer, Sieder, Christian, Melzer, Nima, Mehta, Nehal N., Gori, Tommaso

Volltext

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis von Gordon, Kenneth B, Duffin, Kristina Callis, Bissonnette, Robert, Prinz, Jörg C, Wasfi, Yasmine, Li, Shu, Shen, Yaung-Kaung, Szapary, Philippe, Randazzo, Bruce, Reich, Kristian

Volltext

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results von Silverberg, Jonathan I., de Bruin-Weller, Marjolein, Bieber, Thomas, Soong, Weily, Kabashima, Kenji, Costanzo, Antonio, Rosmarin, David, Lynde, Charles, Liu, John, Gamelli, Amy, Zeng, Jiewei, Ladizinski, Barry, Chu, Alvina D., Reich, Kristian

Volltext

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)... von Blauvelt, Andrew, Gooderham, Melinda, Iversen, Lars, Ball, Susan, Zhang, Lu, Agada, Noah O., Reich, Kristian

Volltext

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial von Thaçi, Diamant, MD, Blauvelt, Andrew, MD, MBA, Reich, Kristian, MD, Tsai, Tsen-Fang, MD, Vanaclocha, Francisco, MD, Kingo, Külli, MD, PhD, Ziv, Michael, MD, BSc, Pinter, Andreas, MD, Hugot, Sophie, MSc, You, Ruquan, MSc, Milutinovic, Marina, MD

Volltext

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials von Griffiths, Christopher E M, Prof, Reich, Kristian, Prof, Lebwohl, Mark, Prof, van de Kerkhof, Peter, Prof, Paul, Carle, Prof, Menter, Alan, MD, Cameron, Gregory S, PhD, Erickson, Janelle, PhD, Zhang, Lu, MS, Secrest, Roberta J, PhD, Ball, Susan, PhD, Braun, Daniel K, MD, Osuntokun, Olawale O, MD, Heffernan, Michael P, MD, Nickoloff, Brian J, MD, Papp, Kim, MD

Volltext

Mouse models of atopic dermatitis: a critical reappraisal von Gilhar, Amos, Reich, Kristian, Keren, Aviad, Kabashima, Kenji, Steinhoff, Martin, Paus, Ralf

Volltext

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study von Blauvelt, Andrew, MD, MBA, Reich, Kristian, MD, Tsai, Tsen-Fang, MD, Tyring, Stephen, MD, PhD, Vanaclocha, Francisco, MD, Kingo, Külli, MD, PhD, Ziv, Michael, MD, BSc, Pinter, Andreas, MD, Vender, Ronald, MD, FRCPC, Hugot, Sophie, MSc, You, Ruquan, MSc, Milutinovic, Marina, MD, Thaçi, Diamant, MD

Volltext

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis von Gordon, Kenneth B, Blauvelt, Andrew, Papp, Kim A, Langley, Richard G, Luger, Thomas, Ohtsuki, Mamitaro, Reich, Kristian, Amato, David, Ball, Susan G, Braun, Daniel K, Cameron, Gregory S, Erickson, Janelle, Konrad, Robert J, Muram, Talia M, Nickoloff, Brian J, Osuntokun, Olawale O, Secrest, Roberta J, Zhao, Fangyi, Mallbris, Lotus, Leonardi, Craig L

Volltext

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis von van de Kerkhof, Peter C.M., MD, PhD, Griffiths, Christopher E.M., MD, Reich, Kristian, MD, PhD, Leonardi, Craig L., MD, Blauvelt, Andrew, MD, MBA, Tsai, Tsen-Fang, MD, Gong, Yankun, PhD, Huang, Jiaqing, MD, PhD, Papavassilis, Charis, MD, PhD, Fox, Todd, RPh, PharmB, ACPR

Volltext

Clinical meaningfulness of complete skin clearance in psoriasis von Strober, Bruce, MD, PhD, Papp, Kim A., MD, PhD, Lebwohl, Mark, MD, Reich, Kristian, MD, Paul, Carle, MD, PhD, Blauvelt, Andrew, MD, Gordon, Kenneth B., MD, Milmont, Cassandra E., PhD, Viswanathan, Hema N., PhD, Li, Joanne, PhD, Pinto, Lionel, PhD, Harrison, David J., PhD, Kricorian, Greg, MD, Nirula, Ajay, MD, PhD, Klekotka, Paul, MD, PhD

Volltext

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and S... von Papp, Kim, MD, PhD, Reich, Kristian, MD, PhD, Leonardi, Craig L., MD, Kircik, Leon, MD, Chimenti, Sergio, MD, Langley, Richard G.B., MD, Hu, ChiaChi, EdM, MS, Stevens, Randall M., MD, Day, Robert M., PhD, Gordon, Kenneth B., MD, Korman, Neil J., MD, PhD, Griffiths, Christopher E.M., MD, FMedSci

Volltext

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the sev... von Simpson, Eric, Bissonnette, Robert, Eichenfield, Lawrence F., Guttman-Yassky, Emma, King, Brett, Silverberg, Jonathan I., Beck, Lisa A., Bieber, Thomas, Reich, Kristian, Kabashima, Kenji, Seyger, Marieke, Siegfried, Elaine, Stingl, Georg, Feldman, Steven R., Menter, Alan, van de Kerkhof, Peter, Yosipovitch, Gil, Paul, Carle, Martel, Philippe, Dubost-Brama, Ariane, Armstrong, John, Chavda, Rajeev, Frey, Steve, Joubert, Yolandi, Milutinovic, Marina, Parneix, Anne, Teixeira, Henrique D., Lin, Chen-Yen, Sun, Luna, Klekotka, Paul, Nickoloff, Brian, Dutronc, Yves, Mallbris, Lotus, Janes, Jonathan M., DeLozier, Amy M., Nunes, Fabio P., Paller, Amy S.

Volltext

Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis von Mader, Julia, MEd, Gallo, Antonio, PhD, Schommartz, Tim, MSc, Handke, Wiebke, PhD, Nagel, Claus-Henning, PhD, Günther, Patrick, RPh, Brune, Wolfram, MD, Reich, Kristian, MD, PhD

Volltext